Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – – Financing includes leading U.S. biotechnology institutional investors and mutual funds –

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.